Vincent Goldschmidt
Institut Gustave Roussy(FR)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research, Colorectal Cancer Treatments and Studies, CAR-T cell therapy research
Most-Cited Works
- → The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry(2021)78 cited
- → Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review(2024)49 cited
- → Immunosenescence, inflammaging, and cancer immunotherapy efficacy(2022)48 cited
- → Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis(2020)42 cited
- → Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1(2020)39 cited
- → BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC).(2023)21 cited
- → Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review(2024)9 cited
- → Antibody drug conjugates in older patients: State of the art(2023)8 cited
- → Impact of Clonal Hematopoiesis–Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial(2024)4 cited
- → Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study(2023)4 cited